Nascent Biotech Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Nascent Biotech has been growing earnings at an average annual rate of 2.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 2.3% per year.
Anahtar bilgiler
2.8%
Kazanç büyüme oranı
38.2%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 2.3% |
| Özkaynak getirisi | n/a |
| Net Marj | n/a |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Gelir ve Gider Dağılımı
Nascent Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -2 | 2 | 0 |
| 31 Mar 24 | 0 | -2 | 2 | 0 |
| 31 Dec 23 | 0 | -2 | 2 | 0 |
| 30 Sep 23 | 0 | -3 | 2 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 1 |
| 31 Mar 23 | 0 | -3 | 2 | 1 |
| 31 Dec 22 | 0 | -3 | 1 | 1 |
| 30 Sep 22 | 1 | -1 | 1 | 1 |
| 30 Jun 22 | 1 | -1 | 1 | 1 |
| 31 Mar 22 | 1 | 0 | 1 | 1 |
| 31 Dec 21 | 2 | 0 | 1 | 0 |
| 30 Sep 21 | 1 | -1 | 1 | 0 |
| 30 Jun 21 | 1 | -1 | 2 | 0 |
| 31 Mar 21 | 1 | -1 | 2 | 0 |
| 31 Dec 20 | 0 | -4 | 4 | 0 |
| 30 Sep 20 | 0 | -4 | 4 | 0 |
| 30 Jun 20 | 0 | -4 | 3 | 0 |
| 31 Mar 20 | 0 | -4 | 3 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 1 |
| 30 Sep 18 | 0 | -2 | 1 | 1 |
| 30 Jun 18 | 0 | -2 | 1 | 1 |
| 31 Mar 18 | 0 | -2 | 1 | 1 |
| 31 Dec 17 | 0 | -2 | 1 | 1 |
| 30 Sep 17 | 0 | -2 | 1 | 1 |
| 30 Jun 17 | 2 | 0 | 2 | 1 |
| 31 Mar 17 | 3 | 1 | 2 | 0 |
| 31 Dec 16 | 3 | 1 | 1 | 1 |
| 30 Sep 16 | 3 | 1 | 1 | 1 |
| 30 Jun 16 | 1 | -3 | 4 | 1 |
| 31 Mar 16 | 0 | -4 | 4 | 1 |
| 31 Dec 15 | 0 | -4 | 4 | 1 |
| 30 Sep 15 | 0 | -5 | 4 | 2 |
| 30 Jun 15 | 0 | -3 | 1 | 2 |
| 31 Mar 15 | 0 | -2 | 0 | 2 |
| 31 Dec 14 | 0 | -2 | 0 | 1 |
| 30 Sep 14 | 0 | -2 | 0 | 1 |
| 30 Jun 14 | 0 | -2 | 0 | 1 |
Kaliteli Kazançlar: NBIO is currently unprofitable.
Büyüyen Kar Marjı: NBIO is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: NBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.
Büyüme Hızlandırma: Unable to compare NBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: NBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: NBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.